Stipple Bio wins Endpoints 2026 award for precision pancreatic cancer therapy
read at Endpoints ↗Positive
Stipple Bio was announced as the winner of the Endpoints 2026 competition, recognized for its work in precision medicine.
The company’s approach focuses on developing targeted treatments for pancreatic cancer, aiming to improve outcomes by tailoring therapy to individual tumor characteristics.
Winning the award highlights the growing interest in precision strategies within oncology and may attract further attention from investors and collaborators.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Endpoints 11 2026 winner Stipple Bio is taking precision to the next level”
read at Endpoints ↗80 words · retrieved 2h ago
comments(0)
5-min edit window · permanent after that